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ABSTRACT PNU145156E (7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-
bis-(1,3-naphthalene disulfonate)) is a naphthalene sulfonic distamycin A derivative that interacts with heparin-binding growth
factors. Because PNU145156E inhibits tumor angiogenesis, it was selected for clinical development. Picosecond time-
resolved fluorescence emission and anisotropy were used to characterize the binding of PNU145156E to the basic fibroblast
growth factor (a protein associated with tumor angiogenesis). A decrease in PNU145156E fluorescence lifetime was observed
as a function of human basic fibroblast growth factor (bFGF) concentration. Nonlinear least-squares fitting of the binding
isotherm yielded Kd  145 nM for a single class of binding sites. Time-resolved anisotropy gave Kd  174 nM. Kd  150 nM
was independently verified by quantitative high-performance affinity chromatography. The displaced volume of the complex,
calculated from its rotational correlation time, fitted a sphere of 1:1 stoichiometry. These results account for the formation of
a tight yet reversible PNU145156E:bFGF complex. An evaluation of PNU145156E fluorescence lifetimes in various solvents
has highlighted the forces involved in stabilizing the complex. These are mostly electrostatic-hydrophobic in nature, with a
relatively low contribution from hydrogen bonding. Both polar and nonpolar groups are involved on the protein-binding site
within a largely hydrophobic cleft. A potential binding trajectory, based on a combination of these results with site-directed
chemical modification and known bFGF x-ray structure, is suggested.
INTRODUCTION
Angiogenesis results from a series of molecular events that
are regulated by stimulators and inhibitors (Klagsbrun and
D’Amore, 1991). This process is fundamental in the devel-
opment of a series of pathologies, such as solid tumor
growth and metastatic spread (Folkman, 1971, 1985). Since
the demonstration of the role of angiogenesis in cancer, the
sequential steps involved in tumor angiogenesis have been
partially elucidated. Thus the search for angiogenesis inhib-
itors has become the focus of several research groups. A
variety of tumor-induced angiogenesis factors have been
identified and are known to have a widespread effect on
different steps of angiogenesis. They play a role in tumor
progression and metastasis through a direct stimulus to cell
division and/or through activation of neovascularization
(Gullino, 1978; Folkman and Klagsbrun, 1987; Blood and
Zetter, 1990; Liotta et al., 1991).
An important class of angiogenesis-promoting proteins is
the heparin-binding growth factors. Its archetypal member,
human basic fibroblast growth factor (bFGF), is involved in
solid tumor development (Burgess and Maciag, 1989; Ba-
silico and Moscatelli, 1992; Presta et al., 1994). bFGF is
associated with the extracellular matrix and basement mem-
brane of endothelial cells, where it is stored and from which
it is released when the extracellular matrix is degraded
(Vlodavsky et al., 1991). A specific structure of heparin and
heparan sulfate proteoglycans is required for bFGF storage
and for productive binding of bFGF to its receptor (Klags-
brun and Baird, 1991; Fernig and Gallagher, 1994; Lindahl
et al., 1994; Ornitz et al., 1995; Faham et al., 1996). Chem-
ical and site-directed mutagenesis studies on bFGF, sup-
ported by x-ray crystallography, have identified separated
functional domains for heparin and for receptor binding
(Baird et al., 1988; Zhu et al., 1990; Eriksson et al., 1993;
Thompson et al., 1994; Springer et al., 1994; Zhu et al.,
1995).
The possible modulation of tumor progression by drugs
that inhibit angiogenic factors is an intriguing approach,
representing a new concept in adjuvant anticancer chemo-
therapy (Herblin et al., 1994; Auerbach and Auerbach,
1994). In the last few years, naphthalene sulfonic distamy-
cin A derivatives were shown to inhibit the binding of
human recombinant bFGF to its receptors, to block in vivo
bFGF-induced vascularization, and to stop neovasculariza-
tion in chorioallantoic membrane (Ciomei et al., 1993). In
particular, PNU145156E was shown to inhibit the growth of
murine tumors in vivo and to have a rather low toxicity
(Sola et al., 1995). These compounds are polysulfonated
naphthylureas structurally related to suramin, which is cur-
rently being investigated as an antitumor agent for the
treatment of advanced malignancies (La Rocca et al., 1990;
Kohler et al., 1992). Suramin causes a nonspecific and
irreversible protein aggregation (Middaugh et al., 1992).
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Unlike suramin, the mechanism of action of naphthalene
sulfonic distamycin A derivatives is suggested to involve
direct binding to the growth factor (Biasoli et al., 1993;
Zamai et al., 1997).
Our present goal is to define the stoichiometry of the
bFGF-drug complex and to understand the nature of the
forces involved in this interaction. As a representative mol-
ecule, we have chosen PNU145156E (7,7-(carbonyl-bis
[imino-N-methyl-4,2-pyrrolecarbonyl-imino(N-methyl-4,2-
pyrrole)carbonylimino]-bis-(1,3-naphthalene disulfonate)
(Scheme 1), which is the lead compound currently under
clinical trial.
The complex between bFGF and PNU145156E was not
yet crystallized. Accordingly, the x-ray structure of the
complex is hitherto unavailable. At the high concentration
required for crystallization of this complex, self-aggregation
of PNU145156E takes place. Alternatively, photon counting
spectrofluorimetry provides a sensitive analytical tool for
the study of the nature of the interaction between bFGF and
PNU145156E at concentrations close to the physiological
range at which self-aggregation does not occur.
We have studied by picosecond single-photon correlation
spectroscopy the fluorescence emission and anisotropy de-
cay profiles of PNU145156E as a function of recombinant
human bFGF concentration. The measurements were car-
ried out in an in vitro cell-free system. Because of the low
quantum yield of the drug, the single-photon counting ap-
paratus was optimized for high detection sensitivity. The
lowest concentration of the drug analyzed was 10 nM. This
sensitivity is comparable to that of 0.1 nM of typical dye
molecules. Binding stoichiometry and reversibility were
then assessed. The affinity of the drug to bFGF was also
verified by high-performance quantitative affinity chroma-
tography. The solvent effect on the PNU145156E lifetime
was evaluated to decipher the forces involved in the drug-
protein interaction. The solvent effect was used to model the
various binding interactions in the complex. Binding affin-
ities for native and carboxymethylated bFGF were compared.
MATERIALS AND METHODS
Reagents and solutions
PNU145156E (MW 1273; 98% purity assessed by elemental analysis and
NMR) was synthesized by Pharmacia & Upjohn. Human recombinant
fibroblast growth factor (bFGF) was produced by Pharmacia & Upjohn or
was obtained from PeproTech (Rocky Hill, NJ). The carboxymethylated
form of bFGF (Cm-FGF) was a gift of Dr. P. Caccia (Caccia et al., 1992).
Both proteins were checked by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. A single band of 17,000 MW was detected for both
proteins. Na2HPO4, NaH2PO4, NaCl, NaHCO3, ethanolamine, sodium
acetate, and high-performance liquid chromatography (HPLC)-grade water
were purchased from Carlo Erba Reagents (Milan, Italy). Anhydrous and
spectroscopic grade 1,4-dioxane, methanol, isopropanol, and acetonitrile
were obtained from Sigma (St. Louis, MO) and Aldrich (Milwaukee, WI).
Accell, N-hydroxysuccinimide ester activated affinity support, was ob-
tained from Waters (Milford, MA). HPLC glass columns for packing
affinity matrices were obtained from Omnifit (Atlantic Beach, NY). All of
the solutions were filtered through 0.22-m filters before use. Phosphate-
buffered saline (PBS) containing 7.5 mM NaH2PO4, 17.5 mM Na2HPO4,
0.15 M NaCl (pH 7.1) was used in affinity chromatography. Fluorescence
binding experiments were run in 6 mM NaH2PO4, 14 mM Na2HPO4, 0.15
M NaCl (pH 7.1). For bFGF immobilization the following buffers were
used: coupling buffer containing 0.2 M NaHCO3, 0.5 M NaCl (pH 8.3);
end-capping buffer containing 0.5 M ethanolamine, 0.2 M NaHCO3, 0.5 M
NaCl (pH 8.3); and washing buffer containing 0.1 M sodium acetate, 0.5 M
NaCl (pH 4.0).
Steady-state fluorescence anisotropy
Steady-state fluorescence anisotropy (Hazan et al., 1995; Alfahel et al.,
1996) was studied in PBS (pH 7.2) at 22°C. The experiments were carried
out on a computer-controlled Perkin-Elmer LS50 spectrofluorimeter (Mil-
ford, CT) equipped with polarizers and a LKB2219 Multitemp II thermo-
static circulator (0.1°C, Stokholm, Sweden). Anisotropy was measured in
the L-format at ex 360 nm/em 450 nm. Under these conditions, total
sample absorptivity was lower or equal to 0.2 O.D., avoiding inner filter or
scattering effects. Slits were set at 4.5 nm in excitation and 20 nm in
emission (Zamai et al., 1997). The G factor was determined for correction.
Data were collected and elaborated by the FLDM Perkin-Elmer anisotropy
obey routine. This technique was used to study the titration of
PNU145156E (2.85 M) by bFGF and Cm-FGF (bFGF carboxymethyl-
ated at Cys69 and Cys87).
Single-photon counting setup
The single-photon counting setup was based on a Spectra Physics Ti-
sapphire Tsunnami laser (Mountain View, CA), which was pumped by a
BeamLok Spectra Physics 10-W argon ion laser and produced a pulse train
of 1 ps duration at a repetition rate of 82 MHz. The Ti-sapphire laser was
run with Spectra Physics “blue” optics and was tuned between 690 and 800
nm. The fundamental frequency was pulse picked by a Spectra Physics
model 3980 apparatus so as to reduce the fundamental pulsed frequency to
4 or 0.8 MHz. The picked pulses were then passed through a Spectra
Physics frequency doubler to produce the desired excitation wavelength
(typically 350–365 nm). The single-photon counting detection system wasScheme 1.
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run at the reversed timing mode and was based on Tennelek and Ortec
state-of-the-art nim-bin components. To minimize the time uncertainty
associated with the single-photon counting time correlation technique, we
used a Hamamatsu 3809u 6  multichannel plate as the light detector.
Wavelength selection was achieved by passing the incoming light through
a double monochromator (CVI, CM112, 1/8 meter; Laser Corporation,
Albuquerque, NM), which was used in its subtractive mode. The full width
at half-maximum (FWHM) of the instrument response was typically 25 ps,
with a best achieved response of 17 ps. The resolution of this setup after
data processing was typically 2–5 ps, depending on the time range of the
time-to-amplitude converter (TAC) Tennelek 862 (Oak Ridge, TN). In this
respect, our setup presents the best performance ever achieved. Anisotropy
measurements were conducted by ensuring the horizontal polarization of
the laser beam by means of a Glan prism. The polarized light was then
passed through a Berek’s polarization compensator (New Focus, Sunny-
vale, CA), which acts like a variable waveplate. This enabled us to rotate
the polarization of the excitation beam while fixing the polarization of the
light entering the double monochromator at vertical polarization. This
configuration avoided complication due to the large G factor of the double
monochromator. Temperature was kept constant at 20°C with a thermo-
statted cell holder that was stabilized to better than 0.05°C by a Neslab
(Portsmouth, NH) chiller.
Time-resolved fluorescence measurements
Experiments were carried out with a total sample absorptivity either lower
than or equal to 0.2 optical density units (O.D.), so as to avoid inner filter
effects and to ensure linearity across the optical path of a 1-cm cuvette.
Samples were excited at 360 nm, the excitation maximum, and their
emission was collected at 440 nm. PNU145156E fluorescence emission
was sampled for 360 s for parallel, perpendicular, and the magic angle
relative orientation between the excitation and emission polarizers (New
Focus). The minimum number of photons, 2–5 K in the peak channel, was
obtained by proper adjustment of neutral density filters. Decay profiles
were obtained at a resolution of 12.5 ps/channel at 20°C. Control back-
ground fluorescence was obtained from samples containing no drug. Data
analyses were performed by noncommercial software. Time-resolved emis-
sion spectral data were fitted to a discrete lifetime model. The fluorescence
decayed according to a double exponential decay. Fluorescence anisotropy
parallel and perpendicular decay components were analyzed according to a
model based either on a single or on a double exponential for both the free
drug and its complex with bFGF. Data processing was done by the ISS
Global analysis program (ISS, Champagne, IL). Other models, e.g., a triple
exponential decay for the complex, resulted in less favorable 2.
Determination of dissociation constants
Fluorescence lifetime titration was used to determine the dissociation
constant, Kd, of the PNU145156E:bFGF complex (Burke and Mi, 1994).
The concentration of PNU145156E was kept constant and equal to 0.31
M in PBS (pH 7.1), and the lifetime was measured at increasing bFGF
concentrations. In control runs, PNU145156E was substituted by buffer.
The model of simple bimolecular association with ligand depletion was
applied to the experimental lifetimes, , measured as a function of bFGF
concentration, [P] (Hulme and Birdsall, 1992):
A Amin Amin Amax/2D  P D Kd
 P D Kd2 4D  P1/2
(1)
where A is , and Amin and Amax are the lifetime values of free (F) and
bound (B) drug, respectively. [D] is the PNU145156E molar concentra-
tion. Kd was determined from Eq. 1. The contribution of protein to the total
intensity was less than 3%.
PNU145156E titration by bFGF was also followed by polarized exci-
tation. Because of the low fluorescence intensity of the drug, 2.15 M
PNU145156E was required in these experiments. The dissociation constant
Kd was determined by applying Eq. 1 to rotational correlation time, 	, as
a function of the molar concentration of bFGF, [P]. In this case, A is 	;
Amin and Amax are the rotational correlation time values of free (	F) and
bound (	B) drug. The contribution of protein to the total intensity was less
than 2%.
All fittings were obtained by nonlinear least-squares regression, using
Prism2 (GraphPad, San Diego, CA), applying a convergence criterion by
which two consecutive iterations reduced the sum of squares by less than
0.01%.
Preparation of high-performance affinity columns
Immobilization of human recombinant bFGF to Accell matrix was carried
out, following a procedure described previously (Zamai and Fassina,
1991). Briefly, 6 mg of bFGF was dissolved in 8 ml of coupling buffer and
incubated with 0.6 g of matrix, for 4–8 h under agitation at 4°C. The
reacted matrix was incubated twice with 20 ml of end-capping buffer for
2 h at room temperature and washed twice with 20 ml of washing buffer.
This washing was repeated twice with 20 ml of coupling buffer and three
times with 20 ml of HPLC-grade water. A blank matrix was prepared by
reacting 1 g of Accell with 20 ml of end-capped buffer, for 2 h at room
temperature, followed by washing as before.
Quantitative high-performance
affinity chromatography
The bFGF-matrix was packed into a 100 	 3 mm inner diameter Omnifit
HPLC glass column. The column was connected to a Pharmacia-LKB
HPLC gradient pump 2249 equipped with a Milton Roy SM4000 program-
mable wavelength detector and a Merck-Hitachi D-2500 Chromato-Inte-
grator. Binding to immobilized bFGF, at 22°C, was followed by continu-
ous (broad zone) elution of PNU145156E at different concentrations.
Accordingly, the immobilized-bFGF column was equilibrated with PBS
elution buffer at a flow rate of 1 ml/min. Then each concentration of
PNU145156E in PBS was continuously eluted through the affinity column
and monitored by UV absorbance at 320 nm, until a plateau of maximum
absorbance was observed. Elution volumes were determined by frontal
analysis as V, the volume at half-maximum absorbance in the sigmoid
elution front. V was corrected for a small shoulder (3% by mass) of
UV-absorbing noninteracting material observed at the void volume V0. The
variation in elution volume V was evaluated by the equation
1/V V0 Kd/MT L0/MT (2)
where V is the volume at which the affinity matrix is half-saturated by the
ligand, V0 is the void volume, Kd is the dissociation constant of the
bFGF:PNU145156E complex, MT is moles of immobilized bFGF at satu-
ration, and [L]0 is the initial concentration of the mobile ligand
PNU145156E (in the broad elution zone, initial and plateau values of [L]
are identical) (Fassina and Chaiken, 1987). The intercept of 1/(V - V0)
versus [L]0 yielded Kd values (inset in Fig. 5).
Solvent effect on the fluorescence lifetime of
PNU145156E
PNU145156E fluorescence lifetime decay was studied in various solvents
to characterize the solvation effect. It is common in such a case to use
empirical solvent parameter analyses that take into account all nonspecific
and specific local solute/solvent interactions. The photophysical indicator
chosen to correlate with the empirical solvent parameters was the relative
quantum yield of the long lifetime component of PNU145156E fluores-
cence, normalized to the amplitude of the lifetime in H2O (i.e.,  
2
2/
2
H2O).  values were fitted using either a single-parameter or mul-
tiparameter approach. In the single-parameter analysis, correlation with
Kosower’s Z value (Kosower, 1968) or with Ditmar and Reinchardt’s ET
30
value (Reichardt, 1990, 1994) was considered. Z values represent solvent
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polarity based on UV absorption spectra of a charge-transfer molecule. ET
30
values represent a combined measure of solvent dipolarity/polarizability
and solvent hydrogen bond donor activity. In the present case, we used
ET
N(30) (i.e., ET
30 normalized by using water and tetramethylsilane (TMS)
as extreme reference solvents; Reichardt, 1990). In the multiparameter
treatment, Krigowski and Fawcett’s procedure (Krygowski and Fawcett,
1975; Glikberg and Marcus, 1983; Zhong-yuan et al., 1985), based on
Ditmar and Reichardt’s ET
30 and Gutmann’s donor number (DN) (Gutmann,
1968), was used. The following equation was applied:
  P1ET
N30 P2DN P3 (3)
where ET
N(30) are ET
30 values normalized to a strong donor solvent (hexa-
methyl phosphoric triamide (HMPT); Reichardt, 1990). They were chosen
as a measure of Lewis acidity. Gutmann’s donor number values, DN, were
chosen as a measure of solvent basicity. P(1) and P(2) are regression
coefficients describing the sensitivity of normalized lifetime to electro-
philic and nucleophilic solvent properties. P(3) is a constant obtained by
the regression. We have also explored the multiparameter approach pro-
posed by Taft (Abraham et al., 1988, and references therein). In this
approach each solvent is characterized by a set of parameters that are
thought to be orthogonal to each other. The advantage is in the possibility
of identifying and isolating each type of solvent interaction. The property
under investigation in a set of solvents can be expressed as
  A0 s* d a
  b (4)
where A0, a, b, d, and s are regression constants; *, nonspecific solute/
solvent interactions, measures the ability of the solvent to stabilize a charge
or a dipole; 
 is the solvent hydrogen bond donor acidity; and  is the
solvent hydrogen bond acceptor basicity. The  parameter is a “polariz-
ability correction term” equal to zero for nonchlorinated aliphatic solvents.
RESULTS
Characterization of PNU145156E:bFGF complex
by following fluorescence lifetime and
anisotropy decays
Time-resolved fluorescence decay profiles of PNU145156E
(0.31 M) were obtained by following fluorescence emis-
sion at 440 nm upon excitation at 360 nm in PBS (pH 7.1)
at 20°C. Fig. 1 A depicts the fluorescence decay profile of
free PNU145156E in buffer, and Fig. 1 B shows the fluo-
rescence decay profile of the drug in the presence of 3.96
M of bFGF. For the free, unbound drug, the best double-
exponential fit resulted in a short component, 1  0.6 ns,
and a long component, 2  10.7 ns, and amplitudes 
1 
0.76 and 
2  0.24, respectively. The long component,
which carries most of the fluorescence quantum yield, was
found to be both environmentally sensitive and reproduc-
ible. The bound drug showed a remarkable decrease of the
long component, 2 6.8 ns, with no change in 1. Relative
amplitudes also changed considerably to 
1  0.96 and 
2
 0.04 (in all cases, 2 of the fitted data ranged between
1.05 and 1.51). Distributional analyses (not shown) with
one or two Lorentzian distributions did not improve the
quality of the two-exponential lifetime fit. A plot of 2, as a
function of bFGF concentration, is shown in Fig. 2. At
bFGF concentrations corresponding to the plateau range of
Fig. 2, a 36% decrease in 2 was observed. The best non-
linear least-squares fit of 2 values was found to follow Eq.
1 (see Materials and Methods). The dissociation constant
(Kd) of the PNU145156E:bFGF complex, obtained by Eq. 1,
was 145  5 nM. This corresponds to a free energy of
interaction 
G  38.4  1.3 kJ mol1. We have also
taken into account the changes in the relative amplitudes,
associated with 1 and 2, using Eq. 1 as a basis for analyses
of the weighted mean lifetime values (mean  1
1  2
2,
Table 1). In this case a dissociation constant of 134  3 nM
was obtained (
G  38.6  0.9 kJ mol1). The fluores-
cence lifetime of the free drug (F  10.75 ns) was deter-
mined by the fitting. The fitted value agrees with our
experimental one (measured in the absence of protein). The
value of the fluorescence lifetime of the fully bound drug
(B  6.82 ns) was determined by extrapolating to infinite
protein concentration. For both analyses (2 and mean), the
linearity of Scatchard plots approximates a single mode of
binding (inset in Fig. 2). The agreement between the two
analyses indicates that the long lifetime component is the
most sensitive parameter in the interaction between the drug
and bFGF (Table 1). In addition, a dilution experiment was
performed. The PNU145156E fluorescence lifetime was
measured to be 6.94 ns in a solution with a bFGF/
PNU145156E ratio of 15.5. This sample was gradually
diluted to bFGF/PNU145156E ratios of 7.7 and 2.54 by
FIGURE 1 Fluorescence emission decays of (A) free and (B) bFGF-
bound PNU145156E in PBS (pH 7.1) at 20°C. [PNU145156E]  0.31 M
and [bFGF]  3.96 M. (Insets) Autocorrelation functions and residuals.
The instrumental lamp function is shown in each case. Calibration: 12.5
ps/channel; exmax  360 nm; emmax  440 nm. Time-resolved emis-
sion spectral data were deconvoluted according to the discrete decay
model.
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adding a 0.31 M solution of PNU145156E. The fluores-
cence lifetime went up to 7.10 ns and to 7.62 ns, respec-
tively. These two data points fall on the fitted curve in Fig.
2. The result indicates the reversibility of the complex
interaction.
Fig. 3 shows the dependence of PNU145156E fluores-
cence anisotropy on complex formation between bFGF and
PNU145156E. Time-resolved anisotropy decays of
PNU145156E (2.15 M in PBS, pH 7.1, at 20°C), in the
absence and in the presence of bFGF (9.79 M), were
compared (Fig. 3, A and B, respectively). PNU145156E
displayed a rapid anisotropy decay that was deconvoluted,
when we used either a single- or a double-exponential
function (Fig. 3 A). The global fit to a single-exponential
function gave an averaged rotational correlation time 	 of
0.08 ns with a 2 value of 1.31 (Table 1). The double-
exponential fit yielded a 	1 of 0.025 ns (
1  0.8) and a 	2
of 0.300 ns (
2 0.2) with a 
2 value of 1.21. The presence
of two rotational correlation times can be explained by the
rodlike structure of PNU145156E (Scheme 1) rotating
around two different axes. In the presence of bFGF, the
results of anisotropy decay changed remarkably (Fig. 3 B).
A dose response increase in PNU145156E averaged rota-
tional correlation time 	 (2 always 1.6) was detected on
titration with bFGF (Fig. 4). The best nonlinear least-
squares analysis of 	 (solid line in Fig. 4) was obtained by
applying Eq. 1. The dissociation constant (Kd) of the com-
plex was 174  4 nM with a free energy of interaction

G  37.9  0.9 kJ mol1. The rotational correlation
time of the free drug (	F), obtained with Eq. 1, is again in
agreement with the averaged rotational correlation time,
	  0.08 ns, measured in the absence of bFGF. The
rotational correlation time of the bound drug, 	B  6.56 ns,
was therefore determined by extrapolation to infinite bFGF
molar concentration in Eq. 1. In this case, too, the Scatchard
plot was linear (Fig. 4, inset).
PNU145156E and bFGF interaction detected and
quantified by QHPAC
To substantiate the results obtained by time-resolved fluo-
rescence, the interaction between PNU145156E and bFGF
was also studied by Quantitative high-performance affinity
chromatography (QHPAC). This is a technique based on
affinity chromatography. Buffer solutions (PBS at pH 7.1)
of the ligand are eluted in a bFGF column, according to the
continuous elution method (see Materials and Methods).
Elution profiles at room temperature of increasing concen-
trations of the drug (mobile phase) throughout a 100 	 3
mm bFGF-column (stationary phase) are shown, overlaid,
in Fig. 5. Their frontal analysis enabled us to quantify the
affinity of PNU145156E for immobilized bFGF (Eq. 2,
inset in Fig. 5). In the presence of a total immobilized
amount of bFGF (MT)  2.7  0.1 nmol, the dissociation
constant for the complex was Kd 150 7 nM. This value
corresponds to a free energy of interaction 
G  38.3 
1.8 kJ mol1 (Table 1). QHPAC also reveals the presence of
some UV-absorbing, noninteracting material that elutes at
the void V0. This material elutes as a shoulder of the drug
profile and accounts for 3% of the total absorbance (Fig.
5). In this way, we could estimate 97% purity of
PNU145156E stock, which accords well with the 98% value
ascertained by traditional analyses (see Materials and
Methods).
PNU145156E fluorescence lifetime in
various solvents
To characterize the nature of the forces involved in the
interaction between PNU145156E and bFGF, the effect of
solvation on PNU145156E was studied by following its
fluorescence lifetime decays. PNU145156E fluorescence
lifetime values, in several solvents, are summarized in Table
2. Evidently, the fluorescence lifetime of the drug is
strongly affected by the chemical nature of the solvent. This
solvent effect cannot be described quantitatively by a single
physical macroscopic solvent parameter such as the dielec-
tric constant, refractive index, or functions thereof. It is
quite common in such a case to use empirical solvent
parameters to characterize the solvation effect of each sol-
vent (Gutmann, 1968; Kosower, 1968; Krygowski and
Fawcett, 1975; Glikberg and Marcus, 1983; Zhong-yuan et
al., 1985; Abraham et al., 1988, and references therein;
Reichardt, 1990, 1994). The use of empirical solvent pa-
rameters has the advantage of taking into account specific
local solvation effects, such as hydrogen bonding and direct
Lewis-type acid-base interactions. The resultant solvent ef-
fect analyses serve as a direct measure of the change in the
environment of the drug (fluorophore).
FIGURE 2 Binding of PNU145156E to bFGF, in PBS (pH 7.1) at 20°C,
as monitored by fluorescence lifetime titration. The fluorophore concen-
tration was 0.31 M, and the bFGF concentration was varied from 0.1 M
to 4.9 M. The variation of the long lifetime component 2 is plotted
versus bFGF concentration. The best nonlinear least-squares fit is repre-
sented by the solid line. The average of duplicate runs is shown, and each
point has a variance of 4% or less. (Inset) Scatchard plot.
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The relative quantum yield of the long lifetime compo-
nent of PNU145156E fluorescence, normalized to the am-
plitude of lifetime in H2O (  2
2/
2
H2O), was chosen to
be correlated with the empirical solvent parameters (Table
2). This procedure resulted in a better correlation than when
performed with either total quantum yield of fluorescence
(
11  
22) or simply 2 lifetime. In fact, both amplitude
and lifetime were found to be solvent sensitive.  was
measured in different solvents and was correlated with
Kosower’s Z value or with Ditmar and Reichardt’s ET
N(30)
value. We found these two correlations to be less successful
(with R  0.850 and R  0.946, respectively) than mul-
tiparameter analysis. Furthermore, these fits (not shown)
suffer from a calculated negative value for the dioxane data
point. A better correlation was found by applying
Krigowski and Fawcett’s procedure, which uses ET
N(30)
values, and Gutmann’s donor number (DN) values. Fig. 6 A
shows the correlation between  and ET
N(30) and DN, re-
sulting in
  22.24ET
N30 4.69DN 6.65
with a correlation coefficient R 0.988. The relative values
of the coefficients indicate that ET
N(30) and the basicity of
solvent (DN) act in opposite directions. Deviations from
linearity are noted in both polar and nonpolar solvents. The
best correlation was obtained by using the Taft multiparam-
eter approach. Fig. 6 B shows the fit to the three Taft
parameters: *, which is a measure for solvent polarity; 
,
which is a measure for solvent acidity; and , which is a
measure for solvent basicity. The best correlation is
  0.272* 10.53
  12.58  4.086
with a noticeable improvement in the correlation (R 
0.998). From the relative weight of the three solvent param-
eters, one can conclude that solvent polarity plays a minor
role in the solvation of PNU145156E. On the contrary,
solvent basicity and acidity play the major part and are
almost equally important. In both the Krigowski and Fawc-
ett and Taft treatments,  decreases with increasing solvent
basicity and increases with increasing solvent acidity. ,
measured in solutions containing 50/50% and 80/20% (v/v)
dioxane/water, are also shown, in Fig. 6, A and B. Finally,
we placed the measured  of the PNU145156E:bFGF com-
FIGURE 3 Time-resolved fluorescence anisotropy decay of 2.15 M
PNU145156E in PBS (pH 7.1) at 20°C: (A) in the absence and (B) in the
presence of 9.79 M bFGF. The solid line represents the global analysis fit.
The respective autocorrelation functions are shown in the insets.
FIGURE 4 Binding of PNU145156E to bFGF, in PBS (pH 7.1) at 20°C,
as monitored by time-resolved fluorescence anisotropy titration. The flu-
orophore concentration was 2.15 M, and the bFGF concentration was
varied from 0.05 M to 9.79 M. Rotational correlation times (	) versus
bFGF concentration are plotted. The best nonlinear least-squares fit is
represented by the solid line. The average of duplicate runs is shown, and
each point has a variance of 4% or less. (Inset) Scatchard plot.
TABLE 1 PNU145156E:bFGF dissociation constants determined by fluorescence and chromatography
Method
PNU145156E
concentration
(M)
Elution volumes
(ml)
Fluorescence decay
times
(ns)
Kd
(nM)

G
(kJ)
Lifetime F B
Decay titration 0.31 10.74 6.82 145  5 38.4  1.3
Anisotropy 	F 	B
Decay titration 2.15 0.08 6.56 174  4 37.9  0.9
Variable Vo V
QHPAC 0.410–1.058 0.80 3.14 150  10 38.3  1.8
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plex on the determined linear correlation (protein in Fig. 6,
A and B). The local environment of the protein is relatively
nonpolar, similar to the isopropanol environment.
PNU145156E steady-state fluorescence
anisotropy: effect of chemical
modification of bFGF
PNU145156E was titrated by using either bFGF or car-
boxymethylated bFGF (Cm-FGF) (Caccia et al., 1992; Za-
mai et al., 1997). The carboxymethylation was at Cys69 and
Cys87. Saturable binding was measured by steady-state flu-
orescence anisotropy of the drug (r) as a function of con-
centration of both the native and the carboxymethylated
proteins (Fig. 7). Fitting was carried out according to Eq. 1.
In this case, A is r; Amin and Amax are the anisotropy values
of free (rF) and bound (rB) drug, respectively (see Materials
and Methods). The apparent dissociation constant of
PNU145156E:Cm-FGF complex (Kd
app  8.6  0.7 M)
was found to be 12 times less favorable than the one of
PNU145156E:bFGF complex (Kd
app  0.72  0.07 M).
The results indicate that the chemical modification of Cys69
and Cys87 considerably affects the interaction of the protein
with the drug. This conclusion is sustained by two facts: 1)
the 3D x-ray structures of Cm-FGF and bFGF are identical
(data not shown), and 2) the lifetime varied by no more than
36% for the drug bound to the native protein.
DISCUSSION
Drugs that are capable of inhibiting tumor angiogenesis are
becoming increasingly important for therapy against solid
tumors. A few in vivo angiogenesis inhibitors have been
characterized, but their putative mechanisms of action have
not been completely clarified (Terano et al., 1993; Seed,
1996).
In the past few years, a novel class of low toxic angio-
genesis inhibitors, named naphthalene sulfonic distamycin
A derivatives, have been synthesized and characterized as
antitumor agents (Biasoli et al., 1993; Ciomei et al., 1993;
Sola et al., 1995). Our research was directed toward better
understanding the interaction of PNU145156E with bFGF,
which had been inferred from previous in vitro observations
(Ciomei et al., 1993; Zamai et al., 1997). We determined the
affinity and reversibility of the binding and the stoichiom-
etry of the complex. In addition, the tightness and the forces
involved in the complex were sought. The major compound
of this family, PNU145156E, is a slightly fluorescent sym-
metrical polysulfonated naphthylurea with a structure re-
sembling that of suramin (Scheme 1). Unlike the fluores-
cence of suramin, which increases drastically upon
interaction with bFGF (Middaugh et al., 1992), the fluores-
cence intensity of PNU145156E is unchanged, even in the
presence of a 30-fold excess of the protein (Zamai et al.,
1997). Data from fluorescence lifetime, anisotropy decay,
and QHPAC confirm the formation of a tight PNU145156E:
bFGF complex (Table 1). The Kd values obtained by the
three different methodologies are similar. Lifetime titration
experiments led to Kd  145  5 nM. Anisotropy decay
studies resulted in a somewhat higher Kd (174  4 nM).
This is most probably due to the higher drug concentration
(15-fold higher than Kd) required for these measurements.
The interaction in a heterogeneous phase between drug and
immobilized bFGF yielded Kd  150  7 nM.
bFGF, with its 146 amino acids, has a single Trp114
residue that is located in a region adjacent to the binding
cleft. There are seven Tyr residues located at the 24, 73,
103, 106, 111, 115, and 124 amino acid positions in the
sequence; only one of them, Tyr124, is expected to be
affected by the binding of bFGF to the drug. Preliminary
steady-state fluorescence quenching experiments on Trp
and Tyr resulted in dissociation constants similar to those
obtained by the three independent methods shown in Table
1. The corresponding Stern-Volmer plots, together with
time-resolved fluorescence anisotropy studies, will be re-
ported elsewhere.
The high value of the free energy of interaction, 
G,
indicates a very strong interaction between the two compo-
nents of the complex. Despite this tightness, binding was
found to be reversible. The linearity of Scatchard analyses
(insets of Figs. 2 and 4) suggests a 1:1 binding stoichiom-
etry. Furthermore, the rotational correlation time allowed
the determination of displaced volume of the PNU145156E:
bFGF complex. Assuming a spherical rotor, the expression
for the rotational diffusion coefficient is
Ds kBT/6V (5)
and the rotational correlation time 	 is related to the rota-
tional diffusion coefficient, Ds, by
	 1/6Ds (6)
where kB is the Boltzmann constant, T is the absolute
temperature (293 K), V is the displaced volume of the rotor,
FIGURE 5 Frontal elution of PNU145156E on the 0.64-ml bed volume
bFGF column. The following concentrations (in M) are overlaid: 1.058,
0.939, 0.719, 0.586, 0.446, 0.410. All elution profiles were recorded up to
binding site saturation (plateau). (Inset) Analysis of elution volumes ac-
cording to Eq. 2.
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and  is the viscosity (1.02 cP). The displaced volume,
calculated from the rotational correlation time of the com-
plex, 	B, is V  26,018 Å
3. The radius of the complex is
r 18.4 Å. Computer-aided modeling of the PNU145156E:
bFGF complex revealed that the calculated rotational cor-
relation time fits a rotating sphere that should be 15%
hydrated, approximating a 1:1 stoichiometry.
The 1:1 complex thus formed exhibits a tight fit between
the protein docking region and the corresponding prede-
signed drug. This is evident from the successful fluores-
cence lifetime analysis of the PNU145156E:bFGF complex
that is based on merely two descret lifetimes. The strong
dependence of () of PNU145156E on the media (Table 2)
could have called for a distribution of lifetimes in a nontight
“breathing” complex in which PNU145156E senses multi-
ple nonhomogeneous binding interactions. However, a two-
Lorentzian distribution (Global Analysis Package, ISS) did
not improve the quality of the lifetime analysis, clearly
indicating a tight, homogeneous complex formation.
PNU145156E fluorescence lifetime decay was studied in
different solvents to characterize the solvation effect and to
gain insight into the nature of the forces involved in its
binding with the protein. Such information on the microen-
FIGURE 6 (A) Correlation between normalized lifetime of
PNU145156E f and 22.24 ET
N(30)  4.69 DN  6.65 in dioxane, (iso)-
propanol, acetonitrile, ethanol, methanol, and water (F). (B) Correlation
between normalized lifetime of PNU145156E f and 0.272*  10.53
 
12.58 4.086 in dioxane, (iso)-propanol, acetonitrile, ethanol, methanol,
and water (F). The solid lines depict the best observed correlations: (A)
R  0.988 and (B) R  0.998. Placed on the correlation lines are the
measured  value in the presence of the protein () and the  values in
50/50% and 80/20% (v/v) dioxane/water, respectively (E).
FIGURE 7 Binding of PNU145156E to bFGF and to Cm-FGF, in PBS
(pH 7.1) at 20°C, as monitored by steady-state fluorescence anisotropy.
The variation of anisotropy, r, is plotted versus bFGF (F) or Cm-FGF (E)
concentration. The fluorophore concentration was 2.85 M. The bFGF
concentration was varied from 0.49 to 33.5 M. The Cm-FGF concentra-
tion was varied from 0.05 to 32.9 M. The best nonlinear least-squares fit
is represented by the solid line. The average of duplicate runs is shown;
each point has a variance of 4% or less.
TABLE 2 Normalized lifetimes of PNU145156E in different solvents
Solvent * (ns) 
1 1 (ns) 
2 2 (ns) 
2
Water 11.160 0.761 0.630 0.239 11.160 1.22
Methanol 7.460 0.828 0.484 0.172 10.366 1.33
Ethanol 3.727 0.908 0.372 0.092 9.683 1.42
(iso)-Propanol 0.967 0.945 0.496 0.055 4.204 1.41
Acetonitrile 2.901 0.926 0.424 0.074 9.370 1.44
Dioxane 1,4 0.377 0.971 0.395 0.029 3.106 1.26
Dioxane 1,4/water 80/20 2.693 0.933 0.375 0.067 9.607 1.21
Dioxane 1,4/water 50/50 5.658 0.866 0.714 0.134 10.092 1.41
Protein# 1.326 0.955 0.600 0.045 7.044 1.51
PBS 11.140 0.752 0.650 0.248 10.740 1.05
*  2
2/
2
H2O.
#Protein concentration  3.96 M.
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vironment of the drug, bound to bFGF, is unlikely to be
obtained from cocrystallization and x-ray of the
PNU145156E:bFGF complex. At the high concentrations
needed for cocrystallization (1 mM), bFGF dimerizes and
the drug undergoes self-aggregation (data not shown). This
explains the failure to crystallize the 1:1 complex (G. Bolis,
personal communication). Therefore, the empirical solvent
single-parameter and multiparameter analyses were applied
as alternatives. In Fig. 6 A, the high values of the positive
ET
N(30) coefficient and the small negative DN basicity co-
efficient indicate that electrophilic solute/solvent interaction
is the dominant solvation mechanism. In Fig. 6 B, the high
values of 
 and  coefficients (solvent acidity and basicity)
play a major role and are almost equally important in the
solvation of PNU145156E. On the contrary, the low value
of the * coefficient implies that solvent polarity plays a
minor role. In both correlations, solvent acidity enhances
the relative quantum yield of the long fluorescent compo-
nent of the drug, whereas solvent basicity has the opposite
effect.
Considering the chemical functional groups in
PNU145156E (i.e., basicity of the pyrroles and acidity of
the sulfonic groups), the resultant analysis agrees with
chemical intuition. These analyses enabled us to interpret
the observed protein-binding effects on PNU145156E flu-
orescence by interpolation of the solvation effect, as shown
in Fig. 6, A and B. Clearly, the docking cleft of bFGF is
relatively nonpolar, similar to that of isopropanol, yet more
polar than that of dioxane. This conclusion is corroborated
by  of PNU145156E in a solution containing 50% water
and 50% dioxane by volume. The dielectric constant of this
solution is similar to that of acetonitrile, which appears in
the lower and less polar part of the correlation shown in Fig.
6. However,  of the 50:50 water-dioxane solution belongs
to the more polar section of the correlation when compared
with acetonitrile. This implies that the presence of small
quantities of bulk (unbound) water, in an otherwise nonpo-
lar environment, greatly enhances the local polarity of the
medium with regard to PNU145156E solvation. Bulk water
molecules are thus presumed to be expelled from the contact
surface between the drug and the protein, which presumably
form a tightly bound complex. Therefore, it is suggested
that the drug-binding domain on the protein involves both
polar and nonpolar groups that are embedded within a
largely hydrophobic core. A delicate balance of all of the
different interactions is entailed. The bulk hydrophobic in-
teractions presumably bring together the drug and the pro-
tein into a tight complex within a single solvation shell.
Furthermore, more specific local interactions, such as hy-
drogen bonding and acid-base interactions, may account for
the additional stability gained in the complex, as evident
from the 
G values.
A “virtual mapping” of the binding sites of the protein
can thus be proposed. In the sequence, an assorted pattern of
amino acids, which combines specific opposing interac-
tions, is expected. Fig. 8 shows, in the 3D structure of
bFGF, a possible path spanning the region from the well-
known sulfate-binding site (where Arg120 and Lys135 are
labeled) to a selenate-binding site, as proposed by Eriksson
(Eriksson et al., 1993), in the vicinity of Lys77 and Glu78.
The positive charges at the sulfate- and selenate-binding
sites are probably the binding hooks. These two sites of the
protein span comparably to the sulfonate groups in the
symmetrical naphthalene moieties of PNU145156E. In ad-
dition, we have found that the selenate site also includes
Cys87, one of the two residues carboxymethylated in Cm-
FGF, whose chemical modification strongly affects the
binding of PNU145156E (Fig. 7). In contrast, Cys69, the
other carboxymethylated residue in Cm-FGF, is located on
the opposite surface of the protein, too far from both sulfate-
and selenate-binding sites. This suggests that chemically
modified Cys87 plays a crucial role in the interaction of the
protein with the drug. The path, drawn in Fig. 8 between the
FIGURE 8 Ribbon diagram of the C
 backbone of bFGF (gray). Amino
acid residues are shown as seen in the x-ray crystal structure of bFGF
(Eriksson et al., 1993). bFGF putative binding cleft of PNU145156E,
spanning the area from the sulfate to the selenate binding sites, is high-
lighted. Blue: Basic (positive charged) side chains; red: acidic (negative
charged) side chains; green: hydrophobic side chains; yellow: hydrogen
bonding making side chains; pink: aromatic side chain. Arg120 and Lys135
are named in the sulfate-binding site, whereas in the selenate-binding site,
Lys77, Glu78, and Cys87 are shown.
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two hooking sites, describes a cleft on the surface of the
protein. Along this cleft, hydrophobic side chains are shown
in green, hydrogen bond-forming side chains are in yellow,
and an aromatic side chain is in pink. This path could
represent the specific local interactions as evidenced by the
solvent effect. It is also in agreement with previous studies
describing the interaction of heparin fragments with bFGF
mutants (Thompson et al., 1994).
The particular balance among the various forces involved
in PNU145156E:bFGF complex accounts for a mode of
interaction different from that of suramin and heparin. On
one hand, suramin, in which benzene rings substitute for
pyrroles, is a common chaotropic agent. It provokes an
extensive and irreversible protein aggregation with a stoi-
chiometry depending on drug concentration (Middaugh et
al., 1992). This can explain the drug side effects observed in
vivo. On the other hand, the interaction with heparin and
heparin fragments (polysulfate-polysaccharide) induces the
dimerization of bFGF (Klagsbrun and Baird, 1991), forming
a complex with a 1:2 stoichiometry (Ornitz et al., 1992;
Thompson et al., 1994). It is this trimeric complex that
positively modulates the binding of bFGF to its receptor
(Yayon et al., 1991; Aviezer et al., 1994), resulting in the
activation of the angiogenesis process. Unlike chaotropic
agents, PNU145156E seems to be more specific for bFGF.
The binding to the protein is driven by the combined hy-
drophobic and hydrogen bonding acceptor sites of the pyr-
role backbone. It is further strengthened by local and spe-
cific interaction of sulfonic charged groups. The advantage
of the proposed binding model lies in the specificity of
the interactions involved. Specificity is demonstrated not
only by the solvent effect, but also by the studies of
point chemical modification. The good tolerability of
PNU145156E in vivo might be ascribed to its specific and
reversible interaction. Its tight binding to bFGF in a 1:1
complex presumably prevents the formation of the 2:1 com-
plex of bFGF with heparin that is essential for its binding to
the receptor, a prerequisite for the activation of the angio-
genic process.
In conclusion, this study indicates that PNU145156E
forms a tight but reversible complex with bFGF. It is most
likely that this interaction covers a large surface of the
protein involving the heparin-binding domain described by
Thompson (1994) and the selenate-binding site proposed by
Eriksson (1993). Thus this relatively small molecule, form-
ing a 1:1 complex with bFGF, is able to prevent biologically
effective dimerization of bFGF.
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